Lonza Group Ltd (LONN):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9903)
◆英語タイトル:Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9903
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:126
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza’s client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company’s key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Venture Financing 19
Odyssey Thera Raises US$3 Million In Venture Financing 19
Private Equity 20
Kainos Capital Acquires InterHealth Nutraceuticals 20
Partnerships 21
Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22
Synpromics Enters into Partnership with Lonza 23
Lonza Enters into Agreement with Denali Therapeutics 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Licensing Agreements 35
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35
CytoDyn Enters into Licensing Agreement with Lonza Sales 36
Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37
Xbiotech Enters Into Licensing Agreement With Lonza Sales 38
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45
Pierre Fabre Enters into Licensing Agreement with Lonza 46
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48
Lonza Enters into Licensing Agreement with arGEN-X 50
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54
Equity Offering 55
Lonza Raise USD2.24 Billion in Rights Offering of Shares 55
Lonza Raises USD871 Million in Private Placement of Shares 56
Debt Offering 57
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 58
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 59
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 60
Asset Transactions 61
PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61
Acquisition 62
Lonza Group Acquires micromacinazione from Cross 62
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63
Lonza Group Acquires PharmaCell 65
Lonza Acquires HansaBioMed Life Sciences 66
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67
Lonza Acquires Triangle Research Labs from PBM Capital 68
Lonza May Acquire Catalent 69
Capsugel Acquires Xcelience 70
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72
Capsugel Acquires Bend Research 73
Capsugel Belgium Acquires Encap Drug Delivery 74
Lonza Group Ltd – Key Competitors 75
Lonza Group Ltd – Key Employees 76
Lonza Group Ltd – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Joint Venture 80
Recent Developments 81
Strategy And Business Planning 81
Nov 05, 2018: Lonza expands capabilities for Parenteral Dosage Forms 81
Oct 08, 2018: Lonza expands HPAPI Development and Manufacturing Capacity for ADC Payloads 82
Sep 20, 2018: Lonza expands IbexsSolutions to offer complete product lifecycle management in one location 83
Sep 12, 2018: Lonza Breaks Ground on Expanded Manufacturing Facility in Greenwood, SC (USA) 84
May 02, 2018: Lonza Consumer Health and Nutrition Invests in Greenwood, SC (USA) Facility to Expand Specialty Ingredients Production 85
Feb 27, 2018: Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil 86
Feb 14, 2018: Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth 87
Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 88
Financial Announcements 89
Jul 25, 2018: Lonza reports strong momentum with organic growth of 8% sales and 11% CORE EBITDA in H1 2018 89
May 04, 2018: Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers 92
Jan 31, 2018: Lonza Reports Record-Breaking Full-Year Results with Double-Digit Lonza Standalone Sales Growth and More than 26% CORE EBIT Growth in a Major Transformational Year 94
Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 98
Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 100
Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 102
Corporate Communications 104
Jun 27, 2017: Lonza’s CHRO Elected to Board of Advance Women in Swiss Business 104
Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 105
Government and Public Interest 106
Oct 09, 2018: Lonza to Host New Webinar – “Streamlining Your QC Testing: Automated Endotoxin Testing and Process Optimization” 106
Product News 107
Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 107
Oct 29, 2018: Lonza to launch XPressEV bioactive functional for the appearance of firmer, fitter skin at in-cosmetics Asia 108
Oct 23, 2018: Lonza’s Capsule Delivery Solutions launches Capsugel Colorista 110
Sep 06, 2018: Lonza releases new technical note: “Construction of a Full-Thickness Skin Model Using RAFT 3D Cell Culture System” 111
Aug 29, 2018: Lonza’s Capsule Delivery Solutions launches Capsugel Colorista 112
Jun 19, 2018: Lonza s Capsule Delivery Solutions Launches Capsugel Vcaps Gen C a New Specialty Polymer Capsule 113
May 22, 2018: Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells 114
Feb 15, 2018: Study Further Positions Lonza’s UC-II A Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market 115
Other Significant Developments 116
Oct 25, 2018: Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year 116
Sep 25, 2018: Lonza’s Capital Markets Day 2018 outlines sustainable growth plans through focus and investment 118
Sep 14, 2018: Lonza launches early-intermediates supply initiative for small-molecule APIs 119
Jul 02, 2018: Lonza Launches New Bioscience Website 120
May 04, 2018: Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics 121
Mar 26, 2018: Lonza to Host New Webinar: “Integrating Devices into Quality Systems” 122
Feb 20, 2018: Lonza Expands Encapsulation and HPAPI Capabilities in North America 123
Dec 14, 2017: Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules 124
Appendix 126
Methodology 126
About GlobalData 126
Contact Us 126
Disclaimer 126

List of Tables
Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Odyssey Thera Raises US$3 Million In Venture Financing 19
Kainos Capital Acquires InterHealth Nutraceuticals 20
Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22
Synpromics Enters into Partnership with Lonza 23
Lonza Enters into Agreement with Denali Therapeutics 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35
CytoDyn Enters into Licensing Agreement with Lonza Sales 36
Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37
Xbiotech Enters Into Licensing Agreement With Lonza Sales 38
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45
Pierre Fabre Enters into Licensing Agreement with Lonza 46
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48
Lonza Enters into Licensing Agreement with arGEN-X 50
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54
Lonza Raise USD2.24 Billion in Rights Offering of Shares 55
Lonza Raises USD871 Million in Private Placement of Shares 56
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 58
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 59
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 60
PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61
Lonza Group Acquires micromacinazione from Cross 62
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63
Lonza Group Acquires PharmaCell 65
Lonza Acquires HansaBioMed Life Sciences 66
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67
Lonza Acquires Triangle Research Labs from PBM Capital 68
Lonza May Acquire Catalent 69
Capsugel Acquires Xcelience 70
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72
Capsugel Acquires Bend Research 73
Capsugel Belgium Acquires Encap Drug Delivery 74
Lonza Group Ltd, Key Competitors 75
Lonza Group Ltd, Key Employees 76
Lonza Group Ltd, Subsidiaries 77
Lonza Group Ltd, Joint Venture 80

List of Figures
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Lonza Group Ltd (LONN):製薬・医療:M&Aディール及び事業提携情報(Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆